Gilead Sciences Inc (NASDAQ:GILD) | Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection

Gilead Sciences Inc (NASDAQ:GILD) [Business Wire] – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company’s New Drug Application for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
Read more on this.

Gilead Sciences Inc. (GILD), with a current market cap of $111.78B, opened this morning at $71.60.
Looking at the stock, its one day range is $70.72 to $72.79 and has traded between $46.53 and $84.88 over the past 12 months.
Priced at 19.17x this year’s forecasted earnings, GILD shares are relatively expensive compared to the industry’s -16.05x forward p/e ratio.

Consensus earnings for the current quarter by the 25 sell-side analysts covering the stock is an estimate of $0.82 per share, which would be $0.34 better than the year-ago quarter and a $0.18 sequential increase. Investors should also note that the full-year EPS estimate of $3.86 is a $1.82 improvement when compared to the previous year’s annual results.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $3.68 Billion. If realized, that would be a 45.45% increase over the year-ago quarter.
In terms of ratings, Robert W. Baird upgraded GILD from Neutral to Outperform (Feb 4, 2014). Previously, Robert W. Baird downgraded GILD from Outperform to Neutral.
The average price target for GILD shares by the analysts covering the stock is $98.42, which is 37.46% above where the stock opened this morning.
Summary (NASDAQ:GILD) :  Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Tag Helper ~ Stock Code: GILD | Common Company name: Gilead | Full Company name: Gilead Sciences Inc (NASDAQ:GILD) .

Share the News | facebooktwittergoogle_plusredditlinkedin |

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

Related Articles

Click for a Random Article: [This Month] | [This Year] | [All Time]

Comments are closed.